Edition:
United States

Abiomed Inc (ABMD.OQ)

ABMD.OQ on NASDAQ Stock Exchange Global Select Market

368.97USD
4:00pm EDT
Change (% chg)

$5.38 (+1.48%)
Prev Close
$363.59
Open
$364.92
Day's High
$369.51
Day's Low
$357.67
Volume
180,192
Avg. Vol
317,984
52-wk High
$450.93
52-wk Low
$144.28

Latest Key Developments (Source: Significant Developments)

Abiomed Receives FDA Approval For Impella Cp® With Smartassist™ And Optical Sensor
Monday, 2 Apr 2018 08:00am EDT 

April 2 (Reuters) - Abiomed Inc ::ABIOMED RECEIVES FDA APPROVAL FOR IMPELLA CP® WITH SMARTASSIST™ AND OPTICAL SENSOR.MARKET APPROVAL FOR ITS IMPELLA CP HEART PUMP WITH SMARTASSIST.  Full Article

Abiomed To Appoint Todd Trapp Chief Financial Officer
Friday, 30 Mar 2018 09:05am EDT 

March 30 (Reuters) - Abiomed Inc ::ABIOMED TO APPOINT NEW CHIEF FINANCIAL OFFICER TODD A. TRAPP.ABIOMED INC - ‍TODD A. TRAPP WILL BE APPOINTED AS VICE PRESIDENT AND CFO, EFFECTIVE APRIL 9, 2018​.  Full Article

Abiomed Receives Approval For Expanded FDA Indication For High Risk PCI Procedures
Wednesday, 14 Feb 2018 08:00am EST 

Feb 14 (Reuters) - Abiomed Inc ::ABIOMED RECEIVES APPROVAL FOR EXPANDED FDA INDICATION FOR HIGH RISK PERCUTANEOUS CORONARY INTERVENTION (PCI) PROCEDURES.  Full Article

Abiomed Receives Approval For Expanded FDA Indication For Cardiomyopathy With Cardiogenic Shock
Tuesday, 13 Feb 2018 08:00am EST 

Feb 13 (Reuters) - Abiomed Inc ::ABIOMED RECEIVES APPROVAL FOR EXPANDED FDA INDICATION FOR CARDIOMYOPATHY WITH CARDIOGENIC SHOCK.ABIOMED INC - APPROVAL EXPANDS PREVIOUS FDA INDICATION FOR ACUTE MYOCARDIAL INFARCTION CARDIOGENIC SHOCK AND PCCS, RECEIVED IN APRIL 2016.  Full Article

Abiomed Reports Q3 Adjusted Earnings Per Share $0.70
Thursday, 1 Feb 2018 07:00am EST 

Feb 1 (Reuters) - Abiomed Inc ::ABIOMED ANNOUNCES Q3 FY 2018 RECORD REVENUE OF $154 MILLION, UP 34% OVER PRIOR YEAR.Q3 GAAP EARNINGS PER SHARE $0.29.Q3 REVENUE $154 MILLION VERSUS I/B/E/S VIEW $147.9 MILLION.Q3 EARNINGS PER SHARE VIEW $0.50 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 REVENUE ABOUT $583 MILLION.SEES FY 2018 REVENUE UP ABOUT 31 PERCENT.SEES Q4 2018 REVENUE ABOUT $164 MILLION.Q3 ADJUSTED EARNINGS PER SHARE $0.70.COMPANY IS INCREASING FISCAL YEAR 2018 GUIDANCE FOR GAAP OPERATING MARGIN TO APPROXIMATELY 26%.FY2018 REVENUE VIEW $575.4 MILLION -- THOMSON REUTERS I/B/E/S.Q4 REVENUE VIEW $162.0 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Abiomed Q3 Gaap Earnings Per Share $0.29
Thursday, 1 Feb 2018 07:00am EST 

Feb 1 (Reuters) - Abiomed Inc ::ABIOMED ANNOUNCES Q3 FY 2018 RECORD REVENUE OF $154 MILLION, UP 34% OVER PRIOR YEAR.Q3 GAAP EARNINGS PER SHARE $0.29.Q3 REVENUE $154 MILLION VERSUS I/B/E/S VIEW $147.9 MILLION.Q3 EARNINGS PER SHARE VIEW $0.50 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 REVENUE ABOUT $583 MILLION.SEES FY 2018 REVENUE UP ABOUT 31 PERCENT.SEES Q4 2018 REVENUE ABOUT $164 MILLION.Q3 ADJUSTED EARNINGS PER SHARE $0.70.‍ INCREASING FISCAL YEAR 2018 GUIDANCE FOR GAAP OPERATING MARGIN TO ABOUT 26%​.  Full Article

Abiomed Reports Preliminary Q3 FY 2018 Revenue Of $154 Mln, Up 34 Pct Over Prior Year
Monday, 8 Jan 2018 07:00am EST 

Jan 8 (Reuters) - Abiomed Inc ::ABIOMED ANNOUNCES PRELIMINARY Q3 FY 2018 REVENUE OF $154 MILLION, UP 34% OVER PRIOR YEAR.Q3 REVENUE $154 MILLION VERSUS I/B/E/S VIEW $147.9 MILLION.  Full Article

Abiomed Q2 earnings per share $0.54
Thursday, 26 Oct 2017 07:00am EDT 

Oct 26 (Reuters) - Abiomed Inc :Abiomed announces Q2 fy 2018 revenue of $132.8 million, up 29% and record u.s. Patient utilization, up 33 pct.Q2 gaap earnings per share $0.54.Q2 revenue $132.8 million versus I/B/E/S view $131.1 million.Q2 earnings per share view $0.38 -- Thomson Reuters I/B/E/S.Abiomed Inc - ‍is increasing lower end of its fiscal year 2018 revenue guidance by $5 million to a new range of $565 million to $575 million​.FY 2019 revenue view $727.3 million -- Thomson Reuters I/B/E/S.Abiomed Inc - ‍increasing its fiscal year 2018 guidance for gaap operating margin to range of 23 pct to 25 pct, from 22 pct to 24 pct​.  Full Article

Abiomed receives FDA PMA approval for Impella RP for right heart failure
Wednesday, 20 Sep 2017 05:33pm EDT 

Sept 20 (Reuters) - Abiomed Inc :Abiomed receives FDA PMA approval for Impella RP for right heart failure.  Full Article

Abiomed maintains fiscal year 2018 revenue guidance
Monday, 28 Aug 2017 05:15pm EDT 

Aug 28 (Reuters) - Abiomed Inc :Says ‍is maintaining its fiscal year 2018 revenue guidance of $560 million to $575 million - SEC filing​.Says is ‍maintaining its fiscal year 2018 guidance for GAAP operating margin in range of 22% to 24%​.FY2018 revenue view $573.8 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Abiomed Q4 GAAP EPS $0.80

* ABIOMED ANNOUNCES Q4 FY 2018 REVENUE OF $174 MILLION, UP 40%, AND TOTAL YEAR REVENUE OF $594 MILLION, UP 33%, OVER PRIOR YEAR